Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: Efficacy and adverse effects with special consideration of peripheral neurotoxicity
Autore:
Mayerhofer, K; Bodner-Alder, B; Bodner, K; Leodolter, S; Kainz, C;
Indirizzi:
Univ Vienna, Sch Med, Dept Gynecol & Obstet, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 necol & Obstet, A-1090 Vienna, Austria
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 5C, volume: 20, anno: 2000,
pagine: 4047 - 4050
SICI:
0250-7005(200009/10)20:5C<4047:PAFCIA>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
STAGE-III; ANTINEOPLASTIC AGENT; TAXOL; PACLITAXEL; NEUROPATHY; CARBOPLATIN; CISPLATIN; COMBINATION; PLATINUM;
Keywords:
paclitaxel; ovarian cancer; response; peripheral neurotoxicity;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Mayerhofer, K Univ Vienna, Sch Med, Dept Gynecol & Obstet, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 ia
Citazione:
K. Mayerhofer et al., "Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: Efficacy and adverse effects with special consideration of peripheral neurotoxicity", ANTICANC R, 20(5C), 2000, pp. 4047-4050

Abstract

Background: The aim of this study was to investigate the response and survival probability of patients with advanced ovarian cancer treated with a combination of paclitaxel and carboplatin as first-line chemotherapy. Additionally we investigated the extent of adverse effects due to chemotherapy with special consideration for peripheral neurotoxicity. Materials and Methods: Thirty-seven women with epithelial ovarian cancer, treated with a combination chemotherapy consisting of paclitaxel and carboplatin, were included in the analysis. A total of 234 courses of paclitaxel/carboplatin were applied. Paclitaxel was administered at a close of 175 mg/m(2) infused over 3 hours, every 21 days. Carboplatin was administered at an area under the concentration-time curve (AUC) of 6. Results: Thirty of the 37 patients responded to the chemotherapy, demonstrating an overall response of 81%. Seven patients died of the disease (19%). The mean overall survival was 20 months (25% quartile: 19, median and 75% quartile not reached). Thirteen patients (34%) developed peripheral neurotoxicity. In 10 cases (76%) neurotoxicity occurred after the fifth and sixth chemotherapy cycle. In all cases of severe neurotoxicity pathologic sensory nerve conduction-measurements were observedIn one patient a weakness of the left leg was observed. Apart from alopecia, other adverse effects were rare Conclusion: This study confirmed the therapeutic benefit of the combination of paclitaxel and carboplatin as first-line chemotherapy in patients with ovarian cancer. Neurologic toxicity, increasing with every cycle of the chemotherapy, was a clinically significant adverse effect in ou,study However; peripheral neuropathy mainly affected sensory fibers, without involving motor nerves.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/09/20 alle ore 13:00:41